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Pathological Q waves as an indicator 
of prior myocardial infarction in 
patients with coronary artery disease 
and diabetes mellitus: a comparison of 
the prevalence and diagnostic accuracy 
according to present and former criteria
ABSTRACT
Introduction. Electrocardiography (ECG) is a widely used diagnostic method for identification of patients 
with previous myocardial infarction (MI). The ECG manifestation of prior MI is the presence of the patho-
logical Q waves. Patients with coronary artery disease (CAD) and diabetes are at high risk of MI. The aim 
of this study was to compare the prevalence and diagnostic accuracy of the pathological Q waves as 
an indicator of prior MI in patients with CAD and diabetes according to the present and former criteria.
Methods. A cross-sectional, multi-centre study was conducted in outpatient clinics across Poland. Family 
physicians performed physical examinations, registered ECGs, and collected relevant information about 
onset of CAD and diabetes, presence and onset of hypertension, dyslipidaemia, heart failure, diabetic 
complications, history of MI, and pharmacotherapy. Centralised manual assessment of the obtained 
ECG tracings was performed. Two definitions of the pathological Q-waves were used — a present one 
according to the Universal Definition of MI and a former one based on the definition of MI developed by 
the World Health Organization.
Results. We enrolled 796 patients (48.1% women, mean age 67.5 ± 10.2 years, and 51.9% men, mean 
age 64.3 ± 10.3 years) into the study. There were 158 patients (19.8%) — 102 men (24.7%) and 56 women 
(14.6%), who met the present definition of the pathological Q waves and 106 patients (13.3%) — 74 men 
(17.9%) and 32 women (8.4%), who met the former definition of the pathological Q waves. The preva-
lence of the pathological Q waves varied due to the certain group of leads. It was highest in the inferior 
leads — 104 and 75 according to the present and former definitions, respectively. Of note, the rate of 
the pathological Q waves increased up to 2.6 times in the lateral leads after the introduction of the less 
restrictive present definition. Sensitivity of prior MI detection by means of the present and former criteria 
was 26.8% and 19.8%, and specificity was 87.0% and 92.8%, respectively. The application of the present 
and former definitions detected prior MI with 65.6% and 71.6% positive predictive value, and with 56.3% 
and 55.6% negative predictive value, respectively.
Conclusions. In the era of reperfusion therapy, ECG appears to be a poor diagnostic tool for detection of 
previous MI due to its low sensitivity. However, it may identify individuals without previous MI with rather high 
specificity. In diabetics with CAD, the present definition of the pathological Q waves increases sensitivity 
of prior MI detection by 7%, with a decrease in specificity by 6% as compared with the former definition.
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Introduction
Electrocardiography (ECG) is a simple and widely 
available method for identification of patients with prior 
myocardial infarction (MI). Although the definition of MI 
has evolved in time, the presence of the pathological 
Q waves still remains significant for previous MI [1, 2]. 
However, due to the recent improvements in the treat-
ment of acute coronary syndromes, we can observe 
a  decrease in the incidence of Q-wave MI and an 
increase in the incidence of non-Q-wave MI [3, 4]. In 
2007, the Joint European Society of Cardiology, Ameri-
can College of Cardiology Foundation, American Heart 
Association, and World Heart Federation Task Force 
introduced a new pathological Q waves definition, which 
is less restrictive than the previous one, so the amount of 
diagnosed MI based on ECG might have increased [5].
Patients with coronary artery disease (CAD) and 
diabetes are at high risk of MI [6, 7]. Several studies 
suggested that diabetes itself is an equivalent for CAD 
and is related with as high risk of MI as in non-diabetic 
patients with previous MI [8–10]. The presence of di-
abetes or CAD is connected with an increased risk of 
cardiovascular morbidity and mortality [11–14]. Impor-
tantly, the coexistence of diabetes and CAD increases 
cardiovascular risk geometrically [15].
The aim of this study was to compare the prevalence 
and diagnostic accuracy of the pathological Q waves 
as an indicator of prior MI in patients with CAD and 
diabetes according to the present and former criteria.
Methods
Study design and conduction
A cross-sectional, multi-centre study was conduct-
ed among patients with CAD and diabetes by family 
physicians in primary care centres in Poland in 2009. 
Inclusion criteria were: 
 — previous angiographically proven clinical diagnosis 
of CAD;
 — previous diagnosis of type 2 diabetes mellitus 
according to the American Diabetes Association 
criteria, and 
 — provision of informed consent for the study partic-
ipation. 
Exclusion criteria consisted of: 
 — presence of ventricular pacing;
 — presence of left or right bundle branch block;
 — presence of left anterior or posterior hemiblock;
 — presence of left ventricular hypertrophy (recognised 
with at least one of seven ECG criteria used, as 
described in our previous publication [16]);
 — presence of pre-excitation;
 — inability of adequate ECG assessment and interpre-
tation due to technical reasons. 
For each patient, a thorough history was taken and 
detailed physical examination was performed. Blood 
pressure was measured by a physician with a mercury 
sphygmomanometer or an automated device in the 
outpatient clinic in a quiet and relaxed environment, 
with the subject seated for at least 10 minutes. The 
average of two measurements was used for the anal-
ysis. Information collected from the medical history 
included: history of hypertension, dyslipidaemia, gout, 
heart failure, diabetic complications (diabetic foot, 
retinopathy, nephropathy, and neuropathy), previous 
MI, and stroke, as well as duration of hypertension, 
diabetes, and CAD. Hypertension was defined as 
systolic blood pressure ≥ 140 mm Hg and/or diastolic 
blood pressure ≥ 90 mmHg or treatment with anti-hy-
pertensive drugs. Measured laboratory parameters 
included: fasting plasma glucose, glycated haemo-
globin (HbA1c), total cholesterol, high-density lipopro-
tein (HDL) cholesterol, low-density lipoprotein (LDL), 
cholesterol, and triglycerides. The aforementioned 
results were collected from patients’ medical docu-
mentation when measured within 12 months. Detailed 
information on participants’ pharmacological treatment 
during the last six months was recorded, including 
the use of metformin, sulfonylurea derivates, insulin, 
acetylsalicylic acid, clopidogrel, statins, fibrates, an-
giotensin-converting enzyme inhibitors, angiotensin 
II receptor blockers, beta-adrenolytics, diuretics, and 
calcium channel antagonists.
The study protocol was approved by the Local Eth-
ics Committee and was performed in accordance with 
the Declaration of Helsinki.
Electrocardiography
Standard supine 12-lead ECGs were registered 
at a 25 mm/s speed and 10 mm/mV gain. They were 
analysed according to the American Heart Association, 
American College of Cardiology Foundation, and Heart 
Rhythm Society Recommendations for the Standardi-
sation and Interpretation of the Electrocardiogram [17]. 
Centralised evaluation was performed in all ECGs 
manually, questionable cases were resolved by an 
independent, experienced cardiologist. Segment du-
ration was the average of three measurements of con-
secutive complexes. In order to detect the pathological 
Q waves we used two definitions: the present one based 
on the Universal Definition of MI endorsed by the Joint 
European Society of Cardiology, American College of 
Cardiology Foundation, American Heart Association, 
and World Heart Federation Task Force for the Redefi-
nition of MI, and the former one based on the definition 
of MI developed by the World Health Organization [5]. 
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Data are presented as numbers (percentages). Qf — former definition of the pathological Q waves; Qp — present definition of the pathological  
Q waves
According to the present definition, a  pathological 
Q-wave is any Q-wave of duration ≥ 0.02 s or QS com-
plex in leads V2–V3 or a Q-wave of duration ≥ 0.03 s and 
amplitude ≥ 0.1 mV or QS complex in leads I, II, aVL, 
aVF, or V4–V6 in any two leads of a contiguous lead 
grouping (I, aVL, V6; V4–V6; II, III, aVF). The former 
criteria defined a pathological Q-wave as a Q-wave of 
duration ≥ 0.04 s and amplitude ≥ 0.1 mV or QS complex 
in any two leads of a contiguous lead grouping.
Statistical analysis
The results are shown as mean ± standard devia-
tion (SD) for continuous variables and as number and 
percentage for categorical variables. Continuous data 
were checked for normal distribution by the use of the 
Shapiro-Wilk W test. Differences in clinical characteris-
tics between patients meeting the present and former 
definitions of the pathological Q waves were assessed 
using the Chi-square test for categorical variables and 
the Student’s t-test for normally distributed continuous 
variables. The non-parametric Mann-Whitney U test was 
applied for comparisons of continuous variables for 
which distribution deviated from normality. A two-sided 
difference was considered significant at p < 0.05. The 
statistical analysis was carried out using the Statistica 
9.1 package (StatSoft, Tulsa, OK, USA).
Results
Out of 1116 potentially eligible patients, 796 subjects 
— 383 women (48.1%), mean age 67.5 ± 10.2 years, 
and 413 men (51.9%),mean age 64.3 ± 10.3 years, were 
enrolled into the study. We excluded 320 participants 
due to: paced rhythm in the assessed ECGs (n = 18), 
the presence of left or right bundle branch block 
(n = 76), the presence of left ventricular hypertrophy 
(n = 200), the presence of ventricular pre-excitation 
(n = 5), or inability of adequate ECG assessment and 
interpretation caused by technical reasons (n = 21).
There were 158 patients (19.8%), 102 men (24.7%) 
and 56 women (14.6%), who met the present definition 
of the pathological Q waves, and 106 patients (13.3%), 
74 men (17.9%) and 32 women (8.4%), who met the 
former definition of the pathological Q waves. We 
observed a  significant increase of the pathological 
Q wave recognition amounting 49.1% comparing 
patients meeting the former definition (n = 106) and 
the present definition (n = 158). The prevalence of the 
pathological Q waves varied due to the certain groups 
of leads. It was the highest in the inferior leads (II, III, 
aVF) — 104 according to the present definition and 
75 according to the former definition. Of note, the rate 
of the pathological Q waves increased up to 2.6 times 
in the lateral leads, after the introduction of the less 
restrictive present definition (Tab. 1).
The statistical analysis of the whole study population 
did not show any differences between patients meet-
ing the present and former criteria of the pathological 
Q waves (Tab. 2). We also did not reveal any differences 
comparing men or women meeting the present and 
former definitions (Tab. 3).
We also compared patients meeting the present 
definition of the pathological Q waves but not fulfilling 
the former criteria with patients meeting the former defi-
nition only. Patients meeting only the former definition 
more often had previous MI, had higher concentration 
of triglycerides, and were more often treated with be-
ta-blockers as compared with those meeting only the 
present definition. There was also a trend showing that 
patients meeting only the former definition were more 
often treated with metformin and less often with sulfo-
nylurea derivates as compared with those meeting the 
present definition (Tab. 4).
Using information from the anamnesis concerning 
previous MI, we calculated sensitivity, specificity, and 
predictive values for prior MI detection by means of 
the present and former definitions of the pathological 
Q waves. The sensitivity was 26.8% and 19.8%, while the 
specificity was 87.0% and 92.8% for the present and for-
mer criteria, respectively. Because of the relatively low 
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Age (years) 65.5 ± 9.6 65.5 ± 9.2 0.96
Height [cm] 170.5 ± 7.8 170.7 ± 7.7 0.83
Weight [kg]) 90.2 ± 15.2 91.3 ± 14.7 0.69
BMI [kg/m2] 31.1 ± 5.4 31.4 ± 5.4 0.78
Waist circumference [cm] 102.2 ± 12.8 103.5 ± 11.7 0.55
Hips circumference [cm] 106.2 ± 11.1 106.1 ± 11.7 0.91
Heart rate [beats/min] 73.3 ± 12.8 73.5 ± 13.3 0.97
Systolic blood pressure [mm Hg] 140.3 ± 17.1 139.1 ± 16.6 0.38
Diastolic blood pressure [mm Hg] 82.7 ± 10.4 81.9 ± 10.0 0.59
Previous MI 99 (62.7%) 73 (68.9%) 0.30
Previous stroke 20 (12.7%) 11 (10.4%) 0.57
Duration of CAD (years) 5.8 ± 5.4 5.8 ± 5.7 0.78
Duration of diabetes (years) 8.5 ± 6.7 8.5 ± 6.2 0.78
Duration of hypertension (years) 12.6 ± 8.3 12.4 ± 8.1 0.92
Duration of dyslipidaemia (years) 9.9 ± 6.2 10.0 ± 5.9 0.72
Duration of heart failure (years) 4.6 ± 4.3 4.4 ± 4.5 0.75
Duration of microangiopathy (years) 5.1 ± 4.3 4.2 ± 3.3 0.40
Duration of heart failure (years) 4.6 ± 4.3 4.4 ± 4.5 0.75
Laboratory tests results:
Fasting plasma glucose [mg/dL] 124.7 ± 32.7 121.8 ± 25.8 0.61
HbA1c (%) 7.2 ± 1.0 7.2 ± 1.0 0.80
Total cholesterol [mg/dL] 203.2 ± 49.0 203.4 ± 48.4 0.88
HDL cholesterol [mg/dL] 48.7 ± 17.4 46.2 ± 14.7 0.50
LDL cholesterol [mg/dL] 119.0 ± 40.4 116.2 ± 36.3 0.87
Triglycerides [mg/dL] 164.0 ± 96.4 173.0 ± 107.4 0.38
Treatment:
ACEI 129 (81.6%) 89 (84.0%) 0.63
ARB 31 (19.6%) 22 (20.8%) 0.82
Acetylsalicylic acid 134 (84.8%) 92 (86.8%) 0.65
Clopidogrel 32 (20.3%) 25 (23.6%) 0.52
Statins 141 (89.2%) 97 (91.5%) 0.54
Fibrates 35 (22.2%) 27 (25.5%) 0.53
Beta-adrenolytics 141 (89.2%) 99 (93.4%) 0.25
Diuretics 85 (53.8%) 59 (55.7%) 0.77
CCA 42 (26.6%) 26 (26.4%) 0.98
Metformin 108 (68.4%) 77 (72.6%) 0.46
Sulfonylurea derivates 62 (39.2%) 36 (34.0%) 0.38
Insulin 48 (30.4%) 34 (32.1%) 0.77
Data are presented as mean values ± SD or numbers (percentages). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin II 
receptor blockers; BMI — body mass index; CAD — coronary artery disease; CCA — calcium channel antagonists; HbA1c — glycated haemoglo-
bin; HDL — high-density lipoprotein; LDL — low-density lipoprotein; MI — myocardial infarction; Qf — former definition of the pathological  
Q waves; Qp — present definition of the pathological Q waves
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Age (years) 65.0 ± 9.3 65.2 ± 9.0 0.84 66.4 ± 10.2 66.7 ± 9.8 0.93
Height [cm] 174.6 ± 5.9 174.2 ± 5.7 0.63 163.1 ± 4.5 162.0 ± 4.0 0.33
Weight [kg] 94.0 ± 13.5 94.0 ± 13.5 0.87 83.5 ± 15.9 85.6 ± 15.9 0.60
BMI [kg/m2] 30.9 ± 4.8 31.1 ± 5.0 0.96 31.5 ± 6.4 32.7 ± 6.4 0.46
Waist circumference [cm] 105.0 ± 11.8 105.0 ± 11.5 0.99 97.3 ± 13.2 100.8 ± 11.3 0.28
Hips circumference [cm] 104.9 ± 10.7 105.1 ± 11.3 1.00 108.6 ± 11.4 109.0 ± 8.5 0.75
Heart rate [beats/min] 72.4 ± 1.0 72.7 ± 1.0 0.09 75.1 ± 12.2 76.1 ± 10.7 0.57
Systolic blood pressure [mm Hg] 139.3 ± 17.0 138.0 ± 17.0 0.60 142.2 ± 17.3 142.8 ± 15.6 0.65
Diastolic blood pressure [mm Hg] 82.8 ± 10.3 82.3 ± 10.5 0.71 82.5 ± 10.7 82.0 ± 9.4 0.94
Previous MI syndrome 66 (64.7%) 51 (68.9%) 0.56 33 (58.9%) 22 (68.8%) 0.81
Previous stroke 12 (11.8%) 7 (9.5%) 0.63 8 (14.3%) 4 (12.5%) 0.81
Duration of CAD (years) 5.2 ± 5.2 5.6 ± 5.5 0.56 7.1 ± 5.6 6.3 ± 5.9 0.39
Duration of diabetes (years) 8.1 ± 6.6 8.4 ± 6.2 0.66 9.1 ± 6.9 9.5 ± 7.0 0.70
Duration of hypertension (years) 11.9 ± 8.0 11.4 ± 7.7 0.76 14.0 ± 8.6 15.3 ± 8.7 0.43
Duration of dyslipidaemia (years) 9.6 ± 6.4 9.8 ± 6.1 0.81 10.5 ± 6.0 11.5 ± 6.4 0.51
Duration of heart failure (years) 3.8 ± 3.7 3.6 ± 3.6 0.86 6.2 ± 5.0 6.4 ± 5.8 0.98
Duration of microangiopathy (years) 4.8 ± 4.0 4.1 ± 2.7 0.76 5.6 ± 4.9 5.2 ± 4.4 0.91
Laboratory rests results:
Fasting plasma glucose [mg/dL] 119.6 ± 20.9 119.4 ± 22.1 0.86 132.8 ± 44.7 128.7 ± 32.9 0.78
HbA1c (%) 7.2 ± 1.0 7.3 ± 1.0 0.72 7.2 ± 1.1 7.3 ± 1.3 0.89
TC [mg/dL] 205.3 ± 47.8 209.4 ± 50.2 0.65 199.8 ± 51.4 191.7 ± 39.7 0.79
HDL [mg/dL] 46.8 ± 17.7 44.6 ± 14.6 0.66 52.1 ± 16.5 53.4 ± 17.0 0.72
LDL [mg/dL] 123.1 ± 34.3 122.8 ± 32.3 0.97 111.5 ± 49.3 102.8 ± 40.0 0.72
TG [mg/dL] 169.9 ± 107.1 181.0 ± 121.5 0.52 153.1 ± 72.7 154.6 ± 50.5 0.52
Treatment:
ACEI 82 (80.4%) 60 (81.1%) 0.91 47 (83.9%) 29 (90.6%) 0.38
ARB 25 (24.5%) 20 (19.6%) 0.71 6 (10.7%) 2 (6.3%) 0.48
Acetylsalicylic acid 85 (83.3%) 62 (83.8%) 0.94 49 (87.5%) 30 (93.8%) 0.35
Clopidogrel 24 (23.5%) 18 (24.3%) 0.90 8 (14.3%) 7 (21.9%) 0.36
Statins 93 (91.2%) 68 (91.9%) 0.87 48 (85.7%) 29 (90.6%) 0.50
Fibrates 24 (23.5%) 19 (25.7%) 0.74 11 (19.6%) 8 (25.0%) 0.56
Beta-adrenolytics 91 (89.2%) 69 (93.2%) 0.17 50 (89.3%) 30 (93.8%) 0.48
Diuretics 58 (56.9%) 42 (56.8%) 0.99 27 (48.2%) 17 (53.1%) 0.66
CCA 24 (23.5%) 18 (24.3%) 0.90 18 (32.1%) 10 (31.3%) 0.93
Metformin 63 (61.8%) 51 (68.9%) 0.33 45 (80.4%) 26 (81.3%) 0.92
Sulfonylurea derivates 34 (33.3%) 25 (33.8%) 0.95 28 (50.0%) 11 (34.4%) 0.16
Insulin 35 (34.3%) 25 (33.8%) 0.72 13 (23.2%) 9 (28.1%) 0.61
Data are presented as mean values ± SD or numbers (percentages). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin II 
receptor blockers; BMI — body mass index; CAD — coronary artery disease; CCA — calcium channel antagonists;HbA1c — glycated haemoglo-
bin; HDL — high-density lipoprotein; LDL — low-density lipoprotein; MI — myocardial infarction; Qf — former definition of the pathological  
Q waves; Qp — present definition of the pathological Q waves
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Table 4. Clinical characteristics of patients meeting the present criteria of the pathological Q waves but not fulfilling 
former criteria, and those meeting the former criteria only
Clinical feature Patients meeting 
Qp but not Qf
n = 52




Age (years) 65.2 ± 10.5 65.7 ± 9.2 0.73
Height [cm] 170.5 ± 8.0 170.5 ± 7.7 0.88
Weight [kg] 87.6 ± 16.2 91.5 ± 14.7 0.26
BMI [kg/m2] 30.1 ± 5.2 31.6 ± 5.5 0.33
Waist circumference [cm] 99.1 ± 14.6 103.7 ± 11.6 0.07
Hips circumference [cm] 106.2 ± 12.1 106.3 ± 10.6 0.87
Heart rate [beats/min] 72.6 ± 12.3 73.6 ± 13.1 0.66
Systolic blood pressure [mm Hg] 142.2 ± 18.0 139.4 ± 142.2 0.55
Diastolic blood pressure [mm Hg] 83.7 ± 11.1 82.2 ± 10.1 0.44
Previous MI 26 (50.0%) 73 (68.9%) <0.05
Previous stroke 9 (17.3%) 11(10.4%) 0.22
Duration of CAD (years) 5.9 ± 5.1 5.8 ± 5.6 0.75
Duration of diabetes (years) 7.9 ± 7.2 8.7 ± 6.4 0.25
Duration of hypertension (years) 12.6 ± 8.4 12.6 ± 8.2 0.82
Duration of dyslipidaemia (years) 8.9 ± 6.4 10.3 ± 6.2 0.18
Duration of microangiopathy (years) 6.6 ± 5.9 4.5 ± 3.4 0.34
Duration of heart failure (years) 5.5 ± 3.5 4.4 ± 4.5 0.33
Laboratory tests results:
Fasting plasma glucose [mg/dL] 129.1 ± 42.9 122.5 ± 26.3 0.41
HbA1c (%) 7.0 ± 0.8 7.3 ± 1.1 0.35
TC [mg/dL] 202.1 ± 51.8 203.9 ± 47.7 0.57
HDL [mg/dL] 51.8 ± 20.6 47.3 ± 15.8 0.42
LDL [mg/dL] 123.8 ± 48.8 116.6 ± 35.8 0.87
TG [mg/dL] 146.0 ± 74.0 172.7 ± 105.0 <0.05
Treatment:
ACEI 40 (76.9%) 89 (84.0%) 0.28
ARB 9 (17.3%) 22 (20.8%) 0.61
Acetylsalicylic acid 42 (80.8%) 92 (86.8%) 0.32
Clopidogrel 7 (13.5%) 25 (23.6%) 0.14
Statins 44 (84.6%) 97 (91.5%) 0.19
Fibrates 8 (15.4%) 27 (25.5%) 0.15
Beta-adrenolytics 42 (80.8%) 99 (93.4%) <0.05
Diuretics 26 (50.0%) 59 (55.7%) 0.50
CCA 14 (26.9%) 28 (26.4%) 0.95
Metformin 31 (59.6%) 77 (72.6%) 0.098
Sulfonylurea derivates 26 (50.0%) 36 (34.0%) 0.052
Insulin 14 (26.9%) 34 (32.1%) 0.51
Data are presented as mean values ± SD or numbers (percentages). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin II 
receptor blockers; BMI — body mass index; CAD — coronary artery disease; CCA — calcium channel antagonists; HbA1c — glycated haemoglo-
bin; HDL — high-density lipoprotein; LDL — low-density lipoprotein; MI — myocardial infarction; Qf — former definition of the pathological  
Q waves; Qp — present definition of the pathological Q waves.
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Figure 1. Diagnostic accuracy of the presence of the pathological Q waves according to the present and former criteria for 
the detection of prior myocardial infarction. Qp — present definition of the pathological Q waves; Qf — former definition 
of the pathological Q waves
false positive rate (present = 13.0%, former = 7.2%), 
the predictive positive value of the pathological Q waves 
presence was 65.6% and 71.6% for the present and 
former definitions, respectively. Because of the high 
false negative rate (present = 73.2%, former = 80.2%), 
their absence truly reflected the absence of previous 
MI in only 56.3% and 55.6% for the present and former 
criteria, respectively (Fig. 1).
Discussion
In our study, the prevalence of the pathological 
Q waves according to the present and former criteria 
was 158 (20%) and 106 (13%), respectively. We ob-
served a 49% increase in the rate of the pathological 
Q wave recognition after the introduction of the pres-
ent definition, resulting in a 49% increase in the ECG 
recognition of prior MI. Parikh et al., while analysing 
the Framingham Heart Study data, noticed a signifi-
cant decrease in MI fatality rates with the prevalence 
rate at a similar level; it was the so-called “the biomark-
er effect” [18]. The number of MIs diagnosed based 
on ECG decreased, but simultaneously the number 
of MIs diagnosed based on biomarkers increased. 
As a result, the total MI prevalence was much higher 
than expected, due to the introduction of more accurate 
and more sensitive cardiac necrosis biomarkers [18].
Focusing on the prevalence of the pathological 
Q waves depending on the location, we observed 
a 160% increase in the rate of the pathological Q wa-
ves in lateral leads, a 29% increase in anterior leads, 
and a 39% increase in inferior leads when the present 
criteria were applied. According to the present ECG 
standards, small Q waves are acceptable in leads I, 
aVL, aVF, and V4–V6 [1], which may explain the sig-
nificant increase of the pathological Q wave diagnosis 
in lateral leads, and we may expect some of them to 
be false positive.
The major finding of this study was very low sensi-
tivity of the pathological Q waves for detecting prior MI, 
according to the present definition, which was approx-
imately 27%, while according to the former definition it 
was 20%. In our study, specificity was 87% and 93% for 
the present and former criteria, respectively. Accord-
ing to older papers based on autopsy as the reference 
method by Horan et al. and Lindvall et al., corre-
sponding values for the sensitivity of the pathological 
Q wave presence were 61% and 76%, and for their 
specificity were 89% and 76%, respectively [19, 20]. 
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In more recent papers by Al-Mohammad et al., San-
dler et al., Asch et al., and Nadour et al., based on 
positron emission tomography, scintigraphy, and 
magnetic resonance imaging (the two last studies) as 
the reference methods, respectively, the sensitivity of 
the pathological Q waves was 41–66%, while the spec-
ificity ranged from 75% to 85% [21–24]. Furthermore, 
in recent years, according to the significant progress 
in treatment of acute coronary syndromes, we can ob-
serve a decreasing proportion of patients diagnosed 
with Q-wave MIs (ranging from 38% to 67%) together 
with a  corresponding increase in the proportion of 
non-Q-wave MIs [4, 25]. This fact seems to be crucial 
for the interpretation of our findings.
Interestingly, Godsk et al. hypothesised that 
the presence of any Q waves in individuals without 
known cardiovascular disease is a predictor of poor 
prognosis [26]. They followed 5381 subjects, of whom 
114 (2.1%) had Q waves in ECG. In their study, the 
primary endpoint, a composite of death and hospital-
isation for CAD, occurred more often in patients with 
Q waves as compared with participants without Q 
waves in ECG (44% vs. 18%; p < 0.001). The authors 
underlined that the presence of even small Q waves is 
a prognostic factor of poor outcome (hazard ratio 1.4; 
95% confidence interval 1.0–2.0; p < 0.05).
There are some limitations of the current study that 
deserve attention. First of all, ECGs were recorded 
in our study using analog, not digital, systems and 
therefore they were analysed manually. Secondly, we 
were not able to use the same electrocardiographic 
devices for all patients in different regions of Poland. 
Thirdly, the information about previous MI was based 
on the patient’s history, not on echocardiography or 
magnetic resonance imaging.
Conclusions
In the era of reperfusion therapy, ECG appears to 
be a poor diagnostic tool for detection of previous MI 
due to its low sensitivity. However, it may identify indi-
viduals without previous MI with rather high specificity. 
In diabetics with CAD, the present definition of the 
pathological Q waves increases the sensitivity of prior 
MI detection by 7%, with a decrease in specificity of 6% 
as compared with the former definition.
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